Cancer BiologybioRxivPreprint
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer
Takashi Sakai, Zofia Piotrowska, Charlotte I. Wang…·Ibiayi Dagogo‐Jack
The paper identifies MTAP loss in 18% of NSCLC specimens and shows PRMT5 inhibitors are effective in MTAP-deleted tumors, with enhanced activity when combined with TKIs.
DOI 10.64898/2026.01.21.700721